Abstract: Transport molecules include a dendrimer and a biologically active molecule. The dendrimer of such transport molecules includes at least one guanidine group, at least one protonated guanidine group, at least one protected guanidine group, at least one amidine group, at least one protonated amidine group, at least one protected amidine group, at least one ureido group, at least one protonated ureido group, at least one protected ureido group, at least one thioureido group, at least one protonated thioureido group, or at least one protected thioureido group. The biologically active molecule is bonded to the dendrimer. A method of increasing the bioavailability of a drug includes bonding the drug to a dendrimer of the invention.

Abstract: The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding the serine/threonine kinase PIM-1, and methods for making and using them; including methods for inducing cellular proliferation, and protecting cardiac cells from hypoxia and cellular apoptosis. The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding PIM-1, and methods for enhancing the regenerative potential of stem cells in the heart.

Abstract: The invention provides methods and compositions for the treatment of asthma and bronchial inflammation, e.g., as induced by an allergen or toxin. In one aspect, the invention provides inhibitors of “Inducible T Cell Kinase” (ITK) polypeptides and methods of making and using them, e.g., as agents and pharmaceutical compositions to treat asthma. In one aspect, the invention is directed to ITK protein expression and/or activity inhibitors. In one aspect, these ITK protein expression and/or activity inhibitors are used with targeting agents. In one aspect, the ITK protein inhibitors of the invention are used to treat asthma. In one aspect, the invention is directed to ITK protein inhibitors as chimeric proteins comprising fragments or altered or truncated forms of ITK protein, or equivalent. In other aspects ITK protein is joined or fused to another moiety (e.g., a targeting domain) or to an antibiotic.

Abstract: The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.

Abstract: An anisotropically elongated thermoelectric nanocomposite includes a thermoelectric material.

Abstract: The invention provides ruthenium-comprising catalysts, and methods of making and using them, for conjugating double bonds in polyunsaturated hydrocarbons, including polyunsaturated fatty acid derivatives, such as natural fats and oils which comprise (contain) more than one carbon to carbon double bond—where the double bonds are separated by, e.g., a methylene, ethylene or propylene or longer group. The invention provides compositions and methods for treating fats and oils comprising “interrupted” (e.g., “methylene-, ethylene- or propylene-interrupted”) double bonds to generate isomers with “conjugated” double bonds. The invention also provides compositions, and methods of making and using them, for making catalysts on a solid support. In one aspect, these catalysts are for alkene isomerization or exchange of alkene hydrogens for other isotopes.

Abstract: Provided herein are small molecule conjugates that are agonists or antagonists of one or more toll-like receptors.

Abstract: The present invention relates to a method for preparing a bifunctional chelator for lanthanide. The method comprises the steps of providing a starting material which has an amino and carboxyl group; protecting the amino with an amino protecting group and the carboxyl with a carboxyl protecting group to produce a protected compound; reacting the protected compound with cyclen to generate a monoalkylated cyclen; reacting the monoalkylated cyclone with an activated compound to generated tetra-alkylated cyclone; removing the amino protecting group with a first protecting group removal reagent; and removing the carboxyl protecting groups with a second protecting group removal reagent to yield a bifunctional chelator having three more carboxyl groups and one or more amino groups.

Abstract: Directional transmission and reception in mobile wireless ad hoc networks may include a number of nodes, in which there is at least a first node and a second node. Each node is associated with a time multiplex frame structure having multiple sub-frames. The sub-frames includes at least a first sub-frame, a second sub-frame, and a third sub-frame. Each of the sub-frames includes multiple time slots. The network further includes one or more directional antennas associated with each of the nodes. The first node of the network is configured to establish communication with the second node within one or more time slots corresponding to the first sub-frame in the time multiplex structure. The first node is also configured to reserve one or more time slots for data transmission with the second node within one or more time slots corresponding to the second sub-frame in the time multiplex structure.

Abstract: A method of characterizing the biological activity of a candidate compound may include exposing cells to the candidate compound, and then exposing the cells to a repetitive application of electric fields so as to set the transmembrane potential to a level corresponding to a pre-selected voltage dependent state of a target ion channel.

Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with hydroxysteroid dehydrogenases that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.

Abstract: The invention provides compositions (e.g., kits) and methods for determine the number of bacteria and other microbes in samples having low concentrations of microbes, for use, e.g., in biological warfare defense, microbe detection and agricultural and environmental sciences.

Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with HDAC that comprise a compound selected from the group consisting of: wherein the substituents are as defined herein.

Abstract: A dual-energy x-ray imaging system searches a moving automobile for concealed objects. Dual energy operation is achieved by operating an x-ray source at a constant potential of 100 KV to 150 KV, and alternately switching between two beam filters. The first filter is an atomic element having a high k-edge energy, such as platinum, gold, mercury, thallium, lead, bismuth, and thorium, thereby providing a low-energy spectrum. The second filter provides a high-energy spectrum through beam hardening. The low and high energy beams passing through the automobile are received by an x-ray detector. These detected signals are processed by a digital computer to create a steel suppressed image through logarithmic subtraction. The intensity of the x-ray beam is adjusted as the reciprocal of the measured automobile speed, thereby achieving a consistent radiation level regardless of the automobile motion.

Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with HDAC that comprise a compound selected from the group consisting of: wherein the substituents are as defined herein.

Abstract: A mobile information technology infrastructure system, including: a server; a broadband network aggregator coupled to the server; at least one wireless communication device coupled to the broadband network aggregator; and a mobile enclosure configured to include the server, the broadband network aggregator, and at least one wireless communication device, wherein the server, the broadband network aggregator, and at least one wireless communication device are aggregated to combine the bandwidth of at least one wireless communication device and to generate information technology services with a single wireless backhaul channel.

Abstract: Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV inhibitors comprising Formula I: wherein the substituents are as described herein.

Abstract: The invention relates to inhibitors of enzymes that disrupt the assembly and function of the mitotic spindle, compositions comprising the inhibitors of Formula (I), kits and articles of manufacture comprising the inhibitors and inhibitor compositions, and methods of using the inhibitors and inhibitor compositions. The inhibitors and inhibitor compositions are useful for treating, preventing or modulating diseases in which mitotic kinesins, including kinesin-like spindle protein (KSP), may be involved; symptoms of such diseases; or the effect of other physiological events mediated by mitotic kinesins, including KSP.

Abstract: A system and method for automated quality assurance including a quality assurance application server for managing quality assurance. The quality assurance application server includes an application configuration module which has a data configuration module configured to define configurable reference fields to be captured and reviewed during the processing of the records. The application configuration module also has a rules configuration module to receive, create or modify a set of rules where the configurable reference fields are selectable when the rules are defined. The system also includes a portal module for processing the received records and applying the set of rules to the record. The portal module includes a quality assurance records review module configured to evaluate and validate the received records and to generate an output utilized to validate the record to ensure compliance with a data recipient, for example payer billing, standards.

Abstract: A method of characterizing the biological activity of a candidate compound may include exposing cells to the candidate compound, and then exposing the cells to a repetitive application of electric fields so as to set the transmembrane potential to a level corresponding to a pre-selected voltage dependent state of a target ion channel.